Physician profile
Alexander R Epperly
NPI 1285993519
$21,109.20
in general payments reported to CMS, 2019-2025
25 companies · $9,800 in 2025
The $9,800 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,672 · 2022: $2,931 · 2023: $2,727 · 2024: $2,980 · 2025: $9,800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,600 · Food and Beverage: $6,040 · Travel and Lodging: $1,275 · Consulting Fee: $1,163 · Education: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,600.00 |
| Food and Beverage | $6,039.87 |
| Travel and Lodging | $1,275.32 |
| Consulting Fee | $1,163.00 |
| Education | $428.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,861.14 | 2021-2025 | |
| Genzyme Corporation | $1,632.14 | 2022-2024 | |
| Janssen Biotech, INC. | $1,554.84 | 2021-2025 | Tremfya |
| Amgen INC. | $1,047.43 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $988.56 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $978.96 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $486.38 | 2021-2023 | Tremfya |
| Lilly USA, LLC | $449.42 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $433.14 | 2021-2025 | Bimzelx |
| Pfizer INC. | $327.89 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $284.15 | 2021-2023 | Absorica Ld, Winlevi, Ilumya |
| Galderma Laboratories, L.P. | $257.85 | 2021-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $184.44 | 2022-2024 | Sotyktu |
| Incyte Corporation | $126.60 | 2022-2025 | Opzelura |
| Regeneron Pharmaceuticals, INC. | $123.94 | 2022-2023 | Dupixent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $117.22 | 2021-2023 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.92 | 2022-2023 | Spevigo |
| Arcutis Biotherapeutics, INC. | $41.35 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $36.40 | 2021-2022 | |
| Biofrontera INC. | $32.67 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Merck Sharp & Dohme LLC | $21.35 | 2023 | Keytruda |
| Dermavant Sciences, INC. | $19.61 | 2024 | Vtama |
| Convatec INC. | $17.85 | 2023 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Organon LLC | $5.78 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Epperly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.